

List of Figures in the Thesis

Sr. No.	Fig. No.	Title	Pg.No.
1.	2.1	The Anatomy of the lung	15
2.	2.2	Chemical Structure of Etoposide	32
3.	2.3	Chemical Structure of Docetaxel	36
4.	2.4	Schematic presentation of interaction of HA and CD44 at cell receptor level.	63
5.	2.5	Chemical Structure of Hyaluronic acid	64
6.	2.6	Alveolar Epithelial cells (A549 cells)	79
7.	3.1	Calibration curve for estimation of Etoposide by UV spectrophotometric method.	93
8.	3.2	Calibration curve for estimation of Etoposide by HPLC	95
9.	3.3	Calibration curve of Etoposide in cell lysates	97
10.	3.4	Calibration curve for Docetaxel by UV spectrophotometric method	99
11.	3.5	Calibration curve for Docetaxel by HPLC	100
12.	3.6	Calibration curve for Docetaxel in Cell Lysates	102
13.	3.7	Calibration curve of protein by BCA method	106
14.	4.1	Contour Plot for Etoposide liposomes	132
15.	4.2	Contour Plot for Docetaxel liposomes	133
16.	5.1(a)	Optimization of HA: Total ETP liposomes weight ratio by zeta potential determination method.	153
17.	5.1(b)	Optimization of HA: Total DOC liposomes weight ratio by zeta potential determination method	154
18.	5.2(a)	Incubation time optimization for HA: ETP liposomes (weight ratio 10:100) grafting at 25 C	154
19.	5.2(b)	Incubation time optimization for HA: DOC liposomes (weight ratio 10:100) grafting at 25 ^o C.	155
20.	5.3(a)	Plot of HA density Vs. Amount of EDC depicting the influence of EDC amount on Etoposide liposomal surface density of HA.	157
21.	5.3(b)	Plot of Particle size of HAETPLIP Vs. Amount of EDC depicting influence of amount of EDC added on particle size of HA grafted Etoposide liposomes.	157
22.	5.4(a)	Plot of HA density Vs. Amount of EDC depicting the influence of EDC amount on Docetaxel liposomal surface density of HA.	159
23.	5.4(b)	Plot of Particle size of HADOCCLIP Vs. Amount of EDC depicting influence of amount of EDC added on particle size of HA grafted	159

		Docetaxel liposomes. All results are expressed as mean\pm S.D. (n=3)	
24	5.5 (a)	FTIR Spectrum of Etoposide liposomes (ETPLIP)	163
25	5.5(b)	FTIR Spectrum of HA grafted Etoposide liposomes (HAETPLIP)	164
26	5.6(a)	FTIR Spectrum of Docetaxel liposomes (DOCLIP)	165
27	5.6(b)	FTIR Spectrum of HA grafted Docetaxel liposomes (HADOCLIP)	166
28	6.1(a)	DSC Thermogram of Pure Etoposide plain drug	182
29	6.1(b)	DSC Thermogram of Blank liposomes (without drug)	183
30	6.1(c)	DSC Thermogram of Etoposide liposomes (ETPLIP)	184
31	6.2(a)	DSC Thermogram of Pure Docetaxel plain drug	185
32	6.2(b)	DSC Thermogram of Blank liposomes (without drug)	186
33	6.2(c)	DSC Thermogram of Docetaxel liposomes (DOCLIP)	187
34	6.3	<i>In vitro</i> drug release profile of Etoposide Drug Solution (ETPSOL),non grafted Etoposide liposomes (ETPLIP) and HA grafted (HAETPLIP) in Phosphate Buffer Saline (pH=7.4)	189
35	6.4	<i>In vitro</i> drug release profile of Docetaxel Drug Solution (DOCSOL),non grafted liposomes (DOCLIP) and HA grafted (HADOCLIP) in Phosphate Buffer Saline (pH=7.4)	191
36	7.1	SEM Image of liposomal DPI of Etoposide	214
37	7.2	SEM image of Liposomal DPI of Docetaxel.	215

38	7.3	In vitro drug release profile of plain Etoposide and developed HA grafted liposomal DPIs of Etoposide with different carriers.	217
39	7.4	In vitro drug release profile of plain Docetaxel and developed HA grafted Docetaxel liposomal DPIs with different carriers.	219
40	8.1(a)	Plot of % Assay Vs. Time in months for LEDPIM at $5 \pm 3^{\circ}\text{C}$ and $25 \pm 2^{\circ}\text{C} / 60 \pm 5\% \text{ R.H.}$ for 12 months.	231
41	8.1(b)	Plot of Volume Mean Diameter (VMD) Vs. Time in months for LEDPIM at $5 \pm 3^{\circ}\text{C}$ and $25 \pm 2^{\circ}\text{C} / 60 \pm 5\% \text{ R.H.}$ for 12 months.	232
42	8.1(c)	Plot of Residual Moisture Content Vs. Time in months for LEDPIM at $5^{\circ}\text{C} \pm 3^{\circ}\text{C}$ and $25 \pm 2^{\circ}\text{C} / 60 \pm 5\% \text{ R.H.}$ for 12 months.	232
43	8.1(d)	Plot of Percentage Drug Retention (PDR) Vs. Time in months for LEDPIM at $5 \pm 3^{\circ}\text{C}$ and $25 \pm 2^{\circ}\text{C} / 60 \pm 5\% \text{ R.H.}$ for 12 months.	233
44	8.1(e)	Plot of Fine Particle Fraction (FPF) % Vs. Time in months for LEDPIM at $5 \pm 3^{\circ}\text{C}$ and $25 \pm 2^{\circ}\text{C} / 60 \pm 5\% \text{ R.H.}$ for 12 months.	234
45	8.2(a)	Plot of % Assay Vs. Time in months for LDDPIM at $5 \pm 3^{\circ}\text{C}$ and $25 \pm 2^{\circ}\text{C} / 60 \pm 5\% \text{ R.H.}$ for 12 months.	236
46	8.2(b)	Plot of Volume Mean Diameter (VMD) Vs. Time in months for LDDPIM at $5 \pm 3^{\circ}\text{C}$ and $25 \pm 2^{\circ}\text{C} / 60 \pm 5\% \text{ R.H.}$ for 12 months.	237
47	8.2(c)	Plot of Residual Moisture Content (%) Vs. Time in months for LDDPIM at $5 \pm 3^{\circ}\text{C}$ and $25 \pm 2^{\circ}\text{C} / 60 \pm 5\% \text{ R.H.}$ for 12 months.	237
48	8.2(d)	Plot of Percentage Drug Retention- PDR (%) Vs. Time in months	238

		for LDDPIM at $5 \pm 3^{\circ}\text{C}$ and $25 \pm 2^{\circ}\text{C}$ / $60 \pm 5\%$ R.H. for 12 months.	
49	8.2(e)	Plot of Fine Particle Fraction- FPF(%) Vs. Time in months for LDDPIM at $5 \pm 3^{\circ}\text{C}$ and $25 \pm 2^{\circ}\text{C}$ / $60 \pm 5\%$ R.H. for 12 months.	239
50	9.1	Cell uptake studies (using confocal microscopy) of ETPLIP, DOCLIP, HAETPLIP and HADOCLIP in A549 cell lines at different time intervals	252
51	9.1(a)	Cell Uptake of non grafted and HA grafted ETP/DOC liposomes in A549 cell lines by Confocal Microscopy in 15 minutes	252
52	9.1(b)	Cell Uptake of non grafted and HA grafted ETP/DOC liposomes in A549 cell lines by Confocal Microscopy in 30 minutes	253
53	9.1(c)	Cell Uptake of non grafted and HA grafted ETP/DOC liposomes in A549 cell lines by Confocal Microscopy in 45 minutes	253
54	9.1(d)	Confocal Microscopy of A549 cells incubated with 6-coumarin solution	253
55	9.2(a)	Jet Stacked Images of ETPLIP	254
56	9.2(b)	Jet Stacked Images of HAETPLIP	255
57	9.2(c)	Jet Stacked Images of DOCLIP	256
58	9.2(d)	Jet Stacked Images of HADOCLIP	257
59	9.3	Cytotoxicity of Etoposide Liposomal formulations and free Etoposide Drug solution after 48 hour incubation time in A549	259

		alveolar epithelial lung cancer cell line,	
60	9.4	Cytotoxicity of Docetaxel Liposomal formulations and free Docetaxel Drug solution after 48 h incubation time in A549 alveolar epithelial lung cancer cell line.	260
61	9.5	Cellular Etoposide levels following treatment with Etoposide in solution and in liposomal formulation obtained by intracellular pharmacokinetic assessment by BCA protein assay method.	261
62	9.6	Cellular Docetaxel levels following treatment with Docetaxel in solution and in liposomal formulation obtained by intracellular pharmacokinetic assessment by BCA protein assay method.	262
63	9.7	Liposomal uptake of ETPLIP by A549 cell line following incubation of cells at 4 ⁰ C and 37 ⁰ C for 30 and 120 minutes.	264
64	9.8	Liposomal uptake of Docetaxel liposomal formulations by A549 cell line following incubation of cells 4 ⁰ C and 37 ⁰ C for 30 and 120 minutes.	264
65	9.9	Cell Cycle Analysis by Flow Cytometry (using PI staining technique) in A549 cells incubated with non grafted and HA grafted Etoposide liposomes. (Blank denotes Untreated cells – cells not treated with drug)	267
66	9.10	Cell Cycle Analysis by Flow Cytometry (using PI staining technique) in A549 cells incubated with non grafted and HA grafted Docetaxel liposomes. (Blank denotes Untreated cells-cells not treated with drug)	267